Welcome to our dedicated page for NMTR news (Ticker: NMTR), a resource for investors and traders seeking the latest updates and insights on NMTR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NMTR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NMTR's position in the market.
9 Meters Biopharma (NASDAQ:NMTR) reported significant advancements in its pipeline during 2021, notably in therapies for short bowel syndrome and celiac disease. The company anticipates Phase 2 topline data for vurolenatide in Q2 2022 and Phase 3 interim analysis for larazotide by early June 2022. Ending 2021, 9 Meters held $47.0 million in cash, securing operations until Q2 2023. Recent leadership additions aim to strengthen its market position. Despite a net loss of approximately $36.8 million in 2021, the company shows promise with its robust pipeline and strategic plans.
RALEIGH, NC / ACCESSWIRE / March 21, 2022 - 9 Meters Biopharma (NASDAQ:NMTR) announced that its CEO, John Temperato, will present at the Maxim Group 2022 Virtual Growth Conference on March 28-30, 2022. The presentation will highlight the company's advanced pipeline, focusing on vurolenatide, a Phase 2 drug for short bowel syndrome, and larazotide, a Phase 3 treatment for celiac disease. Important data for both drugs is expected soon. For further details, visit www.9meters.com.
9 Meters Biopharma (NASDAQ: NMTR) announced that its President & CEO, John Temperato, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 10:00 a.m. (ET). The event runs from March 15-17, 2022, virtually.
The presentation will focus on their pipeline, including vurolenatide for short bowel syndrome and larazotide for celiac disease. A replay will be available for 90 days post-presentation.
9 Meters Biopharma (NASDAQ:NMTR) announced a collaboration with NYU Langone Health to explore the pre-clinical application of its tight junction regulator, NM-102, for an undisclosed autoimmune condition. NM-102 aims to address inflammatory responses linked to gastrointestinal proteins. The company is also advancing larazotide in a Phase 3 trial for Celiac Disease. The collaboration signals potential new treatment avenues for autoimmune disorders, reflecting a commitment to addressing significant unmet medical needs.
9 Meters Biopharma (NASDAQ:NMTR) provides an update on its clinical pipeline. The company is conducting a Phase 2 trial for vurolenatide, aimed at treating adults with short bowel syndrome (SBS), with top-line data expected in Q2 2022. Enrollment is ongoing, hindered by the Omicron surge. Meanwhile, a Phase 3 trial for larazotide in celiac disease is progressing, with an interim analysis set for early June. The company remains confident in meeting its clinical milestones and has sufficient cash flow to support its ongoing studies into 2023.
9 Meters Biopharma (NASDAQ:NMTR) announced promising results published in Critical Care Explorations regarding the use of larazotide for treating pediatric patients with multisystem inflammatory syndrome in children (MIS-C) due to COVID-19. Four patients treated with larazotide showed rapid improvement in gastrointestinal symptoms and shorter hospital stays. Additionally, serum levels of the SARS-CoV-2 spike protein returned to undetectable levels within one day for those treated. A Phase 2a study of larazotide for MIS-C is ongoing, supported by a collaboration with the European Biomedical Research Institute of Salerno.
9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage biopharma company, has announced that John Temperato, its President & CEO, will present at the 2022 BIO CEO & Investor Conference from February 14-17, 2022. The presentation will cover the company's progress on vurolenatide, a Phase 2 treatment for short bowel syndrome, and larazotide, a Phase 3 treatment for celiac disease. The on-demand presentation will be accessible to registered attendees and can also be found on the company's website post-conference.
9 Meters Biopharma (NASDAQ:NMTR) announced that the USPTO has allowed patent application No. 17/239,056 for NM-102, a treatment aimed at enhancing immune checkpoint inhibitors (ICIs) in cancer therapy. The patent supports NM-102's ability to restore intestinal barrier functions, potentially improving cancer treatment outcomes. Preclinical studies indicated NM-102 slows tumor progression and boosts ICIs' efficacy. The company is advancing NM-102 through IND-enabling studies in collaboration with Institut Gustave Roussy.
9 Meters Biopharma has appointed Bethany Sensenig as the new Chief Financial Officer, effective January 18, 2022. Sensenig brings over 20 years of financial leadership experience, notably from her role at Biogen. The company anticipates that her expertise in driving growth and profitability will support its advanced pipeline products, including treatments for short bowel syndrome and celiac disease. Former CFO Ed Sitar is thanked for his contributions during the company's early development.
9 Meters Biopharma (NASDAQ:NMTR) announced its participation in two key investor conferences in January 2022. CEO John Temperato and other management members will engage in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, and the H.C. Wainwright BioConnect Virtual Conference from January 10-13. The company is advancing its clinical candidates, including vurolenatide for short bowel syndrome and larazotide for non-responsive celiac disease. For more information, visit 9meters.com.
FAQ
What is the market cap of NMTR (NMTR)?
